Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 17/20 | 0.52 |
| ▸ | STS | P08842 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3612263 | 1.00 | REN (0.52) | RENSTSTP53POLBANO1 | |
| SCHEMBL13502922 | 0.94 | REN (0.54) | REN | |
| SCHEMBL12631883 | 0.94 | REN (0.56) | REN | |
| SCHEMBL968749 | 0.90 | REN (0.53) | REN | |
| SCHEMBL3608171 | 0.90 | REN (0.64) | REN | |
| SCHEMBL3611603 | 0.90 | REN (0.53) | REN | |
| SCHEMBL3608170 | 0.90 | REN (0.64) | REN | |
| SCHEMBL968751 | 0.90 | REN (0.53) | REN | |
| SCHEMBL1864410 | 0.89 | REN (0.55) | RENSTS | |
| SCHEMBL973589 | 0.88 | REN (0.66) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8487108-B2 | Piperidinyl carbamate intermediates for the synthesis of aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| EP-1966139-B1 | ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS INC (US) | 2011-12-21 | — | — | EP | disclosed |
| US-7745631-B2 | Reacting 2-chloro-3-cyanopyridine with benzyl mercaptan in the presence of a sodium carbonate and an aprotic solvent; hydrolyzing resulting intermediate; no need for purification | JUBILANT ORGANOSYS LIMITED (IN) | 2010-06-29 | — | — | US | disclosed |
| US-7745631-B2 | Reacting 2-chloro-3-cyanopyridine with benzyl mercaptan in the presence of a sodium carbonate and an aprotic solvent; hydrolyzing resulting intermediate; no need for purification | JUBILANT ORGANOSYS LIMITED (IN) | 2010-06-29 | — | — | US | disclosed |
| US-20100048636-A1 | Aspartic Protease Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-02-25 | — | — | US | disclosed |
| EP-1966139-A1 | ASPARTIC PROTEASE INHIBITORS | Vitae Pharmaceuticals, Inc. (US) | 2008-09-10 | — | — | EP | disclosed |
| US-20080139817-A1 | Process For Producing 2-(Phenyl Methyl Thio)-3-Pyridine Carboxylic Acid | JUBILANT ORGANOSYS LIMITED (IN) | 2008-06-12 | — | — | US | disclosed |
| US-20080139817-A1 | Process For Producing 2-(Phenyl Methyl Thio)-3-Pyridine Carboxylic Acid | JUBILANT ORGANOSYS LIMITED (IN) | 2008-06-12 | — | — | US | disclosed |
| WO-2007070201-A1 | ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| WO-2005097748-A1 | PROCESS FOR PRODUCING 2-(PHENYL METHYL THIO)-3-PYRIDINE CARBOXYLIC ACID | JUBILANT ORGANOSYS LIMITED (IN) | 2005-10-20 | — | — | WO | disclosed |
| WO-2005097748-A1 | PROCESS FOR PRODUCING 2-(PHENYL METHYL THIO)-3-PYRIDINE CARBOXYLIC ACID | JUBILANT ORGANOSYS LIMITED (IN) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048636-A1 | Aspartic Protease Inhibitors | DNPEP, PEPD, SERPINB1 | REN 180/4885STS 346/4885TP53 1007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.